Literature DB >> 17068395

Serum trefoil factors in patients with inflammatory bowel disease.

Henning Grønbaek1, Else Marie Vestergaard, Henrik Hey, Jens Nederby Nielsen, Ebba Nexø.   

Abstract

BACKGROUND: Trefoil factors (TFF1-3) play a critical role in mucosal protection and repair in the gastrointestinal tract. The aims of the present study were to examine associations between serum TFF1-3 and clinical and biochemical markers reflecting disease activity and to examine changes in TFF1-3 in patients with inflammatory bowel disease (IBD) before and during high-dose prednisolone treatment and tapering.
METHODS: Serum concentrations of TFF1-3 were quantified in 48 ulcerative colitis (UC) and 50 Crohn's disease (CD) patients with little or moderate activity. Additionally, serum TFF concentrations were determined in patients with severe activity in colon IBD (4 UC and 6 CD) before and during prednisolone treatment with 7 healthy subjects as controls.
RESULTS: Median concentrations of TFF1, TFF2, and TFF3 were significantly increased in IBD patients compared with healthy controls (p < 0.01). TFF3 concentrations correlated with clinical and biochemical parameters of disease activity in UC patients. In addition, a trend towards reduction in TFF concentrations during treatment with prednisolone and concomitant clinical and biochemical remission was observed.
CONCLUSIONS: The present data support the concept that trefoil peptides are upregulated and may play a role in IBD mucosal protection and repair. In UC patients, TFF3 levels were increased in active disease levels correlated with disease activity indices. Due to a large variation, serum TFFs are not a potential marker for disease activity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17068395     DOI: 10.1159/000096591

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  20 in total

Review 1.  Structure, Function, and Therapeutic Potential of the Trefoil Factor Family in the Gastrointestinal Tract.

Authors:  Nayara Braga Emidio; Stuart M Brierley; Christina I Schroeder; Markus Muttenthaler
Journal:  ACS Pharmacol Transl Sci       Date:  2020-06-09

2.  Trefoil factor 1 stimulates both pancreatic cancer and stellate cells and increases metastasis.

Authors:  Thiruvengadam Arumugam; Will Brandt; Vijaya Ramachandran; Tood T Moore; Huamin Wang; Felicity E May; Bruce R Westley; Rosa F Hwang; Craig D Logsdon
Journal:  Pancreas       Date:  2011-08       Impact factor: 3.327

3.  Trefoil factor-3 is not a useful marker of mucosal healing in Crohn's disease treated with anti-TNF-α antibodies.

Authors:  Piotr Eder; Kamila Stawczyk-Eder; Katarzyna Korybalska; Natasza Czepulis; Joanna Luczak; Liliana Lykowska-Szuber; Iwona Krela-Kazmierczak; Krzysztof Linke; Janusz Witowski
Journal:  World J Gastroenterol       Date:  2017-01-07       Impact factor: 5.742

4.  Tests for serum levels of trefoil factor family proteins can improve gastric cancer screening.

Authors:  Susumu Aikou; Yasukazu Ohmoto; Toshiaki Gunji; Nobuyuki Matsuhashi; Hiroshi Ohtsu; Hirona Miura; Kensuke Kubota; Yukinori Yamagata; Yasuyuki Seto; Atsushi Nakajima; James R Goldenring; Michio Kaminishi; Sachiyo Nomura
Journal:  Gastroenterology       Date:  2011-05-27       Impact factor: 22.682

5.  Upregulated expression of hITF in Crohn's disease and screening of hITF Interactant by a yeast two-hybrid system.

Authors:  Huaxiu Shi; Jianlin Ren; Hongzhi Xu; Jinshui Pan; Xiaoyan Hao; Lydia Leyland Barlow; Weiguo Dong
Journal:  Dig Dis Sci       Date:  2010-05-26       Impact factor: 3.199

6.  Over-expression of cathepsin E and trefoil factor 1 in sessile serrated adenomas of the colorectum identified by gene expression analysis.

Authors:  Maria Caruso; James Moore; Gregory J Goodall; Michelle Thomas; Stuart Phillis; Anna Tyskin; Glenice Cheetham; Nancy Lerda; Hiroyuki Takahashi; Andrew Ruszkiewicz
Journal:  Virchows Arch       Date:  2009-01-27       Impact factor: 4.064

7.  Stool and urine trefoil factor 3 levels: associations with symptoms, intestinal permeability, and microbial diversity in irritable bowel syndrome.

Authors:  M M Heitkemper; K C Cain; R J Shulman; R L Burr; C Ko; E B Hollister; N Callen; J Zia; C J Han; M E Jarrett
Journal:  Benef Microbes       Date:  2018-04-10       Impact factor: 4.205

Review 8.  Trefoil factors in inflammatory bowel disease.

Authors:  Luise Aamann; Else Marie Vestergaard; Henning Grønbæk
Journal:  World J Gastroenterol       Date:  2014-03-28       Impact factor: 5.742

Review 9.  Innate immunity modulation by the IL-33/ST2 system in intestinal mucosa.

Authors:  Marina García-Miguel; M Julieta González; Rodrigo Quera; Marcela A Hermoso
Journal:  Biomed Res Int       Date:  2012-12-04       Impact factor: 3.411

10.  Application of serum proteomics to the Women's Health Initiative conjugated equine estrogens trial reveals a multitude of effects relevant to clinical findings.

Authors:  Hiroyuki Katayama; Sophie Paczesny; Ross Prentice; Aaron Aragaki; Vitor M Faca; Sharon J Pitteri; Qing Zhang; Hong Wang; Melissa Silva; Jacob Kennedy; Jacques Rossouw; Rebecca Jackson; Judith Hsia; Rowan Chlebowski; Joann Manson; Samir Hanash
Journal:  Genome Med       Date:  2009-04-29       Impact factor: 11.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.